Manufacturer
Abbvie Ireland NL B.V
Contents
Venetoclax
Indication
Venclexta is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, who have received at least one prior therapy.This indication is approved under accelerated approval based on overall response rate (see Pharmacology: Pharmacodynamics: Clinical Studies under Actions). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Instruction
Should be taken with food: Swallow whole, do not break/chew/crush. Take approx at the same time each day.
Drug interaction
Avoid concomitant use of moderate CYP3A inhibitors, strong or moderate CYP3A inducers, P-gp inhibitors, or narrow therapeutic index P-gp substrates.
Malaysia
